Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Kindred Biosciences, Inc. (NASDAQ: KIN).

Full DD Report for KIN

You must become a subscriber to view this report.


Recent News from (NASDAQ: KIN)

Kindred Biosciences misses by $0.07, beats on revenue
Kindred Biosciences (NASDAQ: KIN ): Q3 GAAP EPS of -$0.39 misses by $0.07 . More news on: Kindred Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 07 2018 16:17
Kindred Biosciences Announces Third Quarter 2018 Financial Results
SAN FRANCISCO , Nov. 7, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2018 and provided update...
Source: PR Newswire
Date: November, 07 2018 16:01
Positive Developments for Treating Patients With Recurrent Malignant Tumors Significant for Novel Therapeutic Strategies
November 1, 2018 Palm Beach, FL – (November 1, 2018) – Multiple myeloma (MM) known as a plasma cell malignancy that affects 14,000 patients per year are fueling the development and clinical activities for new therapies to treat these malignancies. Recent clinical trial resu...
Source: Financial News Media
Date: November, 01 2018 08:00
Kindred Bio up 22% premarket on positive KIND-016 data
Thinly traded Kindred Biosciences (NASDAQ: KIN ) is up  22%  premarket on light volume following its announcement of positive results from a pilot study evaluating IL-31 inhibitor KIND-016 for the treatment of atopic dermatitis in dogs, the leading reason owners visit the veterin...
Source: SeekingAlpha
Date: October, 31 2018 08:35
Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent
SAN FRANCISCO , Oct. 30, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot effectiveness study of KIND-016, a fully caninized...
Source: PR Newswire
Date: October, 30 2018 16:01
Kindred Biosciences to Participate in the CL King 16th Annual Best Ideas Conference, Lake Street Capital Markets 2nd Annual Best Ideas Growth Conference and LD Micro San Francisco Summit
SAN FRANCISCO , Aug. 30, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the LD Micro San Francisco Summit taking place September 4th , the CL King 16th ...
Source: PR Newswire
Date: August, 30 2018 08:31
Kindred Biosciences to Participate in the B. Riley FBR Annual Healthcare Conference
SAN FRANCISCO , Aug. 21, 2018 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the B. Riley FBR Annual Healthcare Conference being held on September 4 th in ...
Source: PR Newswire
Date: August, 21 2018 08:31

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1413.9013.7514.0013.50146,005
2018-02-268.658.558.658.4530,516
2018-02-238.608.608.608.4025,725
2018-02-228.608.508.658.3538,940
2018-02-218.558.508.708.4040,562

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1718,06228,78762.7436Short
2018-12-144,8697,59964.0742Short
2018-12-136,14713,33646.0933Short
2018-12-121,7133,71646.0980Short
2018-12-114,3519,01248.2801Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on KIN.


About Kindred Biosciences, Inc. (NASDAQ: KIN)

Logo for Kindred Biosciences, Inc. (NASDAQ: KIN)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: KIN)

      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: September, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: September, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 09 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: July, 24 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: June, 28 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: June, 21 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: June, 21 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: June, 19 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: June, 06 2018

       

       


      Daily Technical Chart for (NASDAQ: KIN)

      Daily Technical Chart for (NASDAQ: KIN)


      Stay tuned for daily updates and more on (NASDAQ: KIN)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: KIN)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in KIN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of KIN and does not buy, sell, or trade any shares of KIN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/